Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;33(6):1206-12.
doi: 10.2337/dc09-1040.

Prediction of type 1 diabetes in the general population

Mikael Knip  1 , Sari Korhonen, Petri Kulmala, Riitta Veijola, Antti Reunanen, Olli T Raitakari, Jorma Viikari, Hans K Akerblom
Affiliations

Prediction of type 1 diabetes in the general population

Mikael Knip et al. Diabetes Care. 2010 Jun.

Abstract

Objective: To evaluate the utility of GAD antibodies (GADAs) and islet antigen-2 antibodies (IA-2As) in prediction of type 1 diabetes over 27 years in the general population and to assess the 6-year rates of seroconversion.

Research design and methods: A total of 3,475 nondiabetic subjects aged 3-18 years were sampled in 1980, and 2,375 subjects (68.3%) were resampled in 1986. All subjects were observed for development of diabetes to the end of 2007. GADAs and IA-2As were analyzed in all samples obtained in 1980 and 1986.

Results: A total of 34 individuals (1.0%; 9 developed diabetes) initially had GADAs and 22 (0.6%; 9 developed diabetes) IA-2As. Seven subjects (0.2%) tested positive for both autoantibodies. The positive seroconversion rate over 6 years was 0.4% for GADAs and 0.2% for IA-2As, while the inverse seroconversion rates were 33 and 57%, respectively. Eighteen subjects (0.5%) developed type 1 diabetes after a median pre-diabetic period of 8.6 years (range 0.9-20.3). Initial positivity for GADAs and/or IA-2As had a sensitivity of 61% (95% CI 36-83) for type 1 diabetes. Combined positivity for GADAs and IA-2As had both a specificity and a positive predictive value of 100% (95% CI 59-100).

Conclusions: One-time screening for GADAs and IA-2As in the general childhood population in Finland would identify approximately 60% of those individuals who will develop type 1 diabetes over the next 27 years, and those subjects who have both autoantibodies carry an extremely high risk for diabetes. Both positive and inverse seroconversions do occur over time reflecting a dynamic process of beta-cell autoimmunity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Probability of remaining nondiabetic in Finnish subjects initially positive (n = 34, 9 developed type 1 diabetes) or negative for GADAs (n = 3,441, 9 developed type 1 diabetes); B: positive (n = 22, 9 developed type 1 diabetes) or negative (n = 3453, 9 developed type 1 diabetes) for IA-2As; C: positive for GADAs and/or IA-2As (n = 49; 11 developed type 1 diabetes) or negative for both autoantibodies (n = 3426, 7 developed type 1 diabetes); and D: in those initially positive for two (n = 7, all developed type 1 diabetes), one (n = 42, 4 developed diabetes), or no (n = 3,426, 7 developed type 1 diabetes) antibodies.
Figure 1
Figure 1
A: Probability of remaining nondiabetic in Finnish subjects initially positive (n = 34, 9 developed type 1 diabetes) or negative for GADAs (n = 3,441, 9 developed type 1 diabetes); B: positive (n = 22, 9 developed type 1 diabetes) or negative (n = 3453, 9 developed type 1 diabetes) for IA-2As; C: positive for GADAs and/or IA-2As (n = 49; 11 developed type 1 diabetes) or negative for both autoantibodies (n = 3426, 7 developed type 1 diabetes); and D: in those initially positive for two (n = 7, all developed type 1 diabetes), one (n = 42, 4 developed diabetes), or no (n = 3,426, 7 developed type 1 diabetes) antibodies.
See this image and copyright information in PMC

Comment in

References

    1. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–229 - PubMed
    1. Knip M: Disease-associated autoimmunity and prevention of insulin-dependent diabetes mellitus. Ann Med 1997;29:447–451 - PubMed
    1. Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazzo GF, Gale EAM, Bosi E: Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995;38:816–822 - PubMed
    1. Verge C, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926–933 - PubMed
    1. Kulmala P, Savola K, Petersen JS, Vähäsalo P, Karjalainen J, Löppönen T, Dyrberg T, Åkerblom HK, Knip M: the Childhood Diabetes in Finland Study Group Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes: a population-based study. J Clin Invest 1998;101:327–336 - PMC - PubMed

Publication types